Business Context and Reporting Period
This Form 8-K Current Report is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on June 14, 2024. The filing reports a material modification to the rights of security holders regarding a reverse stock split.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity data. The only quantitative metric provided relates to share count adjustments:
- Pre-split Outstanding Shares: Approximately 4.7 million.
- Post-split Outstanding Shares: Approximately 0.6 million.
Material Changes
The Company effected a 1-for-8 reverse stock split of its Common Stock, effective at 5:00 p.m. Eastern Time on June 14, 2024.
- Trading Impact: Trading on the Nasdaq Capital Market resumed on a split-adjusted basis on June 17, 2024, under a new CUSIP number (79400X404).
- Fractional Shares: No fractional shares were issued; holders entitled to fractions received cash in lieu thereof based on the closing price on the Effective Date.
- Ownership: The split does not change any stockholder's ownership percentage (except for cash-in-lieu adjustments) and does not reduce authorized shares.
- Adjustments: All outstanding options, warrants, and shares reserved under equity incentive plans were adjusted accordingly.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the reverse split and its timing. The Company notes that risks include general market conditions and other risks detailed in its Form 10-K for the fiscal year ended December 31, 2023, and Form 10-Q for the quarter ended March 31, 2024. The Company undertakes no obligation to update these statements.
Investor Verification Checklist
- Verify the new CUSIP number (79400X404) for trading purposes.
- Confirm the adjusted number of shares held in brokerage accounts post-split.
- Check for cash payments received in lieu of fractional shares.
- Review the adjusted exercise prices and share counts for any outstanding options or warrants.
- Consult the Company's recent 10-K and 10-Q filings for financial health metrics not included in this 8-K.